☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - June 2022

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Relugolix / estradiol / norethisterone tablets (Ryeqo®) have been accepted for restricted use in the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. The restriction limits use to patients who have not responded to or are unsuitable for conventional therapies (first line treatments), such as tranexamic acid, hormonal contraceptives and intrauterine delivery systems.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - June 2022' by emailShare 'SMC Update - June 2022' on FacebookShare 'SMC Update - June 2022' on TwitterShare 'SMC Update - June 2022' on LinkedInShare 'SMC Update - June 2022' on reddit


No Comments to “SMC Update - June 2022”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.